Page 2431 - Williams Hematology ( PDFDrive )

2402 Index Index 2403

Aplastic anemia, treatment (Cont.): L-Arginine, 286 formulations, 1515
investigative, 527 Arginine butyrate, 775 mechanism of action, 197, 198, 332–333
rituximab, 526 ARID1A, 235t, 1788 for NK/T-cell lymphoma, 1702
splenectomy, 527 ARID1B, 1788 ASPEN syndrome, 770
supportive care, 522 Arp2/3 complex, 1841 Aspergillus infections
Aplastic crisis Arry-614, 1360 as cause of hemolytic anemia, 820
in hereditary spherocytosis, 674 ARSA, 439 in chronic granulomatous disease, 1030,
in sickle cell disease, 767 Arsenic, megaloblastic anemia and, 606t 1032
Apo-1. See Fas (CD95) Arsenic hydride, 52., 810 cutaneous, 2104–2105, 2105f
Apoferritin, 618 Arsenic trioxide, 335–336 after hematopoietic cell transplantation,
Apoferritin mRNA, 624f, 625f for acute myelogenous leukemia, 1404 369
Apolipoprotein A (ApoA), 1976 for acute promyelocytic leukemia, 1404, in immunocompromised host, 383
Apolipoprotein A1 (ApoA1), 2288 1405t, 1406 prevention, 389
Apolipoprotein E receptor 2 (apoER2), 2237 for myelodysplastic syndromes, 1360 Aspirin
Apolipoprotein H. See β2Glycoprotein (GP)I Arsine gas, 810 for antiphospholipid syndrome in
(apolipoprotein H) Artemis, 1166f, 1167, 1214t pregnancy, 2245
Apoptosis Arterial thrombosis avoidance in hemophilia A, 2121
BCR-ABL and, 1444 in antiphospholipid syndrome, 2238 for chronic myeloproliferative disorders,
caspases in, 203–205, 204f in chronic myeloproliferative neoplasms, 2081
definition, 203 2080–2081 clinical uses, 404, 404t
of eosinophils, 951 consultative approach to, 47 dosage, 404t
genotoxic stress and, 209 in disseminated intravascular coagulation, for essential thrombocythemia, 1313, 2081
hematologic diseases and, 209–211 2204 hemolytic anemia and, 708
of hematopoietic stem cells, 74–75 in heparin-induced thrombocytopenia, hemostatic effects, 2075
macrophages in, 1060–1061, 1061f 2028 maternal ingestion
of neutrophils, 285, 992 in hereditary thrombophilia, 2226–2227 effect on fetus and newborn, 112, 112t
signal transduction pathways and, in nonatherosclerotic arteries, 2293 platelet aggregation in newborn and,
208–209, 208f pathobiology, 2291–2292, 2291t 107
suppressors, 205–208 pathogenesis, 2292–2293 mechanism of action, 404, 404t, 2073–2074
Apoptosome, 205 platelet activation in, 2245 myeloma incidence and, 1709
Apoptotic cells, 23 site-specific characteristics, 2292 for myocardial infarction, 2295–2296
APP (amyloid precursor protein), 1848 systemic factors, 2246 for peripheral arterial disease, 2297
APRIL, 309 thrombophilia testing in, 2228–2229 platelet effects, 2073–2075
Aprotinin, 2318 tissue factor and phospholipids in, for polycythemia vera, 1300, 2081
APS. See Antiphospholipid syndrome (APS) 2245–2246 resistance, 2075
aPTT. See Activated partial thromboplastin vs. venous thrombosis, 2291t for stroke prevention, 2297
time (aPTT) vorapaxar for prevention of, 2076–2077 for thrombotic thrombocytopenic
Arabidopsis thaliana, 293 Arthralgia, history of, 6 purpura, 2256
Arabinosyl cytosine. See Cytarabine (ara-C) Arthritis for venous thromboembolism, 2276
Ara-C. See Cytarabine (ara-C) in acute myelogenous leukemia, 1381 Asplenia, 868
Arachidonic acid, 288, 1854, 1857f, 1874 history of, 6 Asthma
Arachidonic acid metabolism, 1016, 2058 rheumatoid. See Rheumatoid arthritis eosinophils and, 954, 955t
Arachidonic acid metabolites, 284t, 286t, septic, 771 mast cells in, 969
1876–1877 Arthropathy sickle cell disease and, 769
Arasulfatase A, 439 in hemochromatosis, 643 ASXL1, 226t, 227t, 229t, 1346t, 1351
ARDS (acute respiratory distress syndrome), in hemophilia, 2117, 2117f, 2118f AT. See Antithrombin (AT)
2201, 2204–2205, 2208 Arthropod bites, 2102 AT1-type receptors, 1879
Arf, 1883 Ascariasis, 957t Ataxia-pancytopenia, 530t
Argatroban, 399 Ascorbic acid. See Vitamin C (ascorbic acid) Ataxia-telangiectasia, 1226–1227
clinical uses, 399 ASCT2 (SLC1A5), 197, 198 acute lymphoblastic leukemia and, 1507
for heparin-induced thrombocytopenia, ASO-PCR (allele-specific oligonucleotide clinical features, 1215t, 1226–1227
2030, 2031t polymerase chain reaction), 1716 gene mutations, 1227, 1575t
pharmacology, 399 L-Asparaginase, 332–333 laboratory features, 1214t
for unstable angina, 2296 for acute lymphoblastic leukemia, 1515, lymphomas and, 1575t
Arginase-1, 1013t, 1014 1516, 1517 pathophysiology, 1226
Arginine, for sickle cell disease, 777t adverse effects, 333, 1519t, 1520 treatment, 1227

Kaushansky_index_p2393-2506.indd 2402 9/21/15 3:21 PM